Press release Biocartis Group NV

Biocartis 2023 half-year results webcast on 26 September 2023

PRESS RELEASE REGULATED INFORMATION                                                                                                                              

21 September 2023, 07:00 CEST

BIOCARTIS 2023 HALF-YEAR RESULTS WEBCAST ON 26 SEPTEMBER 2023

Mechelen, Belgium, 21 September 2023 – Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company (Euronext Brussels: BCART), will report its 2023 half-year results and provide further updates on the status of its reorganization and financing & recapitalization plans on 26 September 2023 at 07:00 CEST.

That day, Roger Moody, Biocartis’ Chief Executive Officer and George Cardoza, Biocartis’ Chief Financial Officer will also host a conference call with a live webcast presentation at 14:30h CEST / 13:30h BST (UK) / 08:30h EDT (US).

• The live webcast presentation will be available through this link on the day of the event.
• Only participants who want to follow the event over the phone, are requested to register for the webcast presentation here. Upon registration, each participant will be provided with dial-in numbers and a unique personal PIN. While not required, it is recommended to join 5-10 minutes prior to the start of the call.

Instructions are provided to ensure the necessary audio applications are downloaded and installed. Users can obtain these programs at no charge. The conference call and webcast will be conducted in English. A replay of the webcast will be available on the Biocartis investors’ website shortly after.

--- END ---
More information:
Investor Relations Biocartis
e-mail [e-mail]

About Biocartis

With its revolutionary and proprietary Idylla Platform, Biocartis (Euronext Brussels: BCART) aspires to enable personalized medicine for patients around the world through universal access to molecular testing, by making molecular testing actionable, convenient, fast and suitable for any lab. The Idylla Platform is a fully automated sample-to-result, real-time PCR (Polymerase Chain Reaction) based system designed to offer in-house access to accurate molecular information in a minimum amount of time for faster, informed treatment decisions. Idylla's continuously expanding menu of molecular diagnostic tests address key unmet clinical needs, with a focus in oncology. This is the fastest growing segment of the molecular diagnostics market worldwide. Today, Biocartis offers tests supporting melanoma, colorectal, lung and liver cancer, as well as for sepsis. More information: www.biocartis.com. Follow us on Twitter, Facebook or LinkedIn.